News

A rise in cases of the waterborne pathogen.

Shionogi’s investigational therapy, ensitrelvir, demonstrated a median time-to-symptom resolution of approximately 1 day shorter in the antiviral group versus placebo.

The American Gastroenterological Association recommends fecal microbiota-based therapies for recurrent or severe C difficile infections and other gastrointestinal issues.

Participants of a recent study who experienced more daily cognitive symptoms had a greater likelihood of reporting moderate interference with functioning, less likelihood of full-time employment, and greater severity of depressive symptoms.

Cefepime-enmetazobactam (Exblifep, Orchid Pharma) was given the federal nod for the indication of treating complicated urinary tract infections (cUTI) in adults.

The federal agency did not request further trials for the investigational therapy, cefepime-taniborbactam, but wanted more information about its chemistry, manufacturing, and controls.

CDC reveals trends in M pneumoniae infections before, during, and after the pandemic.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

Innovative treatments, challenging prevention, and impact of climate change.

The federal government is working to provide greater access to testing and treatment.

Phase 3 study shows ART treatment in maintaining viral load suppression

The mRNA-1647 vaccine demonstrated approximately a 50% efficacy against human cytomegalovirus (HCMV).

Eric D. Donnenfeld, MD, discusses 3 uncommon yet highly infectious eye diseases, emphasizing the importance of timely treatment and preventative measures.

New review article outlines the evidence and future work that needs to be done with regards to doxycycline post-exposure prophylaxis (doxy-PEP).

Study compares immune responses in cancer vs. non-cancer patients.

Accessibility to direct-acting antivirals affecting low and middle-income countries.

A clinician reviews the literature and offers some insights on the role of this antibiotic in bone, joint, and hardware infections.

CDC is advocating for the adoption of alternative antimicrobial agents.

Investigators recently noted that despite a decrease in adolescent hospital visits during the height of the pandemic, there was an increase in sexually transmitted infections (STIs) in this population group.

Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.

The impact of the new surveillance criteria on case identification.

This week, increased risk of long COVID in individuals who have tested positive for the virus, advancements in the preservation of the microbiome offer new strategies for healthcare-associated infections (HAIs), FDA-approved GSK's bepirovirsen signaling the company's goal to cure viral hepatitis, CDC considers changing 5-day COVID isolation guideline, and the first victim of the Alaskapox virus highlights the critical need for increased research into emerging infectious diseases.

A recently published study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.

Study reveals HEV adaptation during treatment.

It affects a limited number of Dole-branded and private label salad kits, and no cases of illness associated with the Dole recall have been reported.

CDC is currently investigating an outbreak of gastrointestinal illness.

Advancements in microbiome preservation offer new solutions for HAI.

A senior microbiologist gives audiences of sister brands, Infection Control Today and Contagion, an insight into leishmaniasis, a potentially fatal disease.

Oregon resident catches plague through a cat-to-human transmission.

The Centers for Disease Control and Prevention (CDC) considers changing its previous guidance.